Onco Actu du 24 septembre 2019

	4.10 DÉP., DIAG. & PRONO. - POUMON
Biomarker Research Advancing to Predict Small Cell Lung Cancer Treatment Response [Genome Web] For the MGH team, Farago said that their molecular signature is multiple steps away from being ready to be used in the clinic.
	4.12 BIOPSIES LIQUIDES
PGDx Shares New MSI Data, Provides Update on FDA Bid for Pan-Cancer IVDs [Genome Web] In the current study, PGDx — with collaborators at Memorial Sloan Kettering Cancer Center and Johns Hopkins University — described the development of the company's technique for gleaning MSI status from circulating tumor DNA NGS data, which involves barcoding, error correction, and various computational methods to align reads to define microsatellite loci.
	4.16 DÉP., DIAG. & PRONO. - PANCRÉAS
Why Can’t We Stop Pancreatic Cancer? [NY Times] There is little a person can do to prevent it, and there is nothing comparable to mammography or colonoscopy to screen for it when it is most amenable to cure.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
FDA Decision Expands Market for Exact Sciences’ Cologuard Test [Xconomy] The FDA has approved the test, Cologuard, for eligible, average-risk patients ages 45 and older, which expands the market that Madison, WI-based Exact can address with its product.
	5. TRAITEMENTS
Heart damage from cancer drugs linked to faulty genes [Imperial College London] The faulty titin gene was found in 7.5 per cent of CCM (cancer-therapy induced cardiomyopathy) patients, compared to 0.7 per cent of healthy individuals.
For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment [NCI] Overall, the trial’s findings show that “even in the era of precision medicine,” a tandem autologous stem cell transplant should be used “in most patients with high-risk neuroblastoma.”
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Notorious KRAS: Taking down cancer researchers’ biggest foe [C&EN] After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?
	5.10 TRAITEMENTS - ESSAIS
Cancer centers stretching to keep up with pharma's oncology interest [Biopharma Dive] DiPersio estimates about a quarter to a third of cancer clinical investigations are open for a year without anyone enrolling in them. He said empty trials are not only an "economic drain" on institutions because of the regulatory and logistical work that goes into opening a site, but they're also reflective of broader enrollment issues.
Merck, Pfizer execs explain how they tap sites for cancer trials [Biopharma Dive] BioPharma Dive spoke separately with Eric Rubin, vice president of global clinical oncology at Merck Research Laboratories, and Chris Boshoff, chief development office at Pfizer Oncology, about how they select sites and communicate with the physicians who run cancer clinical trials.
	5.12 IMMUNOTHÉRAPIES
Orchestrating an Antitumor Immune Response: A Preview of the Fifth International Cancer Immunotherapy Conference [Cancer Research Catalyst] The Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival will be held September 25-28 in Paris. The meeting will feature talks on cancer prevention, immune checkpoint blockers, cell- and non-cell-based immunotherapies, vaccination strategies, resistance mechanisms, and new targets, among other topics.
	5.12.6 IMMUNOTHÉRAPIES - AMM
EMA Recommends Extension of Indications for Avelumab [ESMO] New indication concerns combination with axitinib for the first-line treatment of adults with advanced RCC.
	5.16 TRAITEMENTS - CHIRURGIE
Paging Dr. Robot [New Yorker] Giu­lianotti was the first surgeon to perform more than a dozen robotic procedures, ranging from kidney transplants to lung resections. In the operating room, he relies on one robot: a multi-armed, one-and-a half-­million-dollar device named the da Vinci.
	5.2 PHARMA
A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M in cash to beef up the pipeline [EndPoints] The Boulder, CO-based biotech says it plans to steer the first drug to the clinic in the second half of next year. Their new target is fibroblast activation protein alpha, or FAP, which is expressed on a broad range of tumors.
	5.2.3 PHARMA - ÉCONOMIE
Pharma friend Innate wants $100M Nasdaq IPO [Fierce Biotech] Innate's leading pipeline med is monalizumab, a midstage checkpoint inhibitor designed to block functions of NK and cytotoxic T cells. AstraZeneca paid Innate $170 million (€148 million) to license the anti-NKG2A antibody and secure an option on five other prospects a year ago, with a few hundred million in biobucks also wedded to the deal.
Deepening US footprint, AstraZeneca-partnered French biotech Innate shoots for $100M IPO [EndPoints] The company is working on three classes of products: broad-spectrum immune checkpoint inhibitors, tumor antigen targeting, and suppressive factors of the TME. They are currently testing monalizumab, their lead drug, in collaboration with AstraZeneca for solid tumors, including SCCHN (head and neck) and CRC (colorectal).
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU [Bayer] The EMA approval of larotrectinib is based on pooled clinical trial data of 102 patients (93 patients from the primary analysis population and an additional 9 patients with primary CNS tumors) across the Phase I trial of adult patients, the Phase II NAVIGATE trial in adult and adolescent patients and the Phase I/II pediatric SCOUT trial.
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation [Astellas] If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years.
	5.6 ESMO
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019 [Lilly] Verzenio® (abemaciclib) Phase 3 data included in ESMO Presidential Symposium and Official Press Program: Positive overall survival results to be presented from MONARCH 2, evaluating Verzenio with fulvestrant for the treatment of women with HR+, HER2- advanced breast cancer whose cancer grew or spread following endocrine therapy.
	6. LUTTE CONTRE LES CANCERS
Science Surgery: ‘Does cancer affect the future development of children?’ [Cancer Research UK] While these long-term side effects seem extremely worrying, the risk of each treatment needs to be weighed up against the benefits. And, thanks to research, the chances of people experiencing long-term effects from cancer treatment they had when they were young are becoming lower and lower.
Three ways global links help our researchers carry out life-changing research on World Cancer Research Day [Institute of Cancer Research] Cancer research is a team effort that crosses all borders, and on World Cancer Research Day we highlight three ways our researchers contribute to and benefit from these global ties.
	6.1 OBSERVATION
16.9M people and counting are surviving cancer each year — but we can do better [The Hill] A look beneath the surface shows that cancer health disparities cut across racial, ethnic, socioeconomic, gender, sexual, and geographic lines, and they influence every element of cancer risk, diagnosis, and treatment.
	6.12 ETHIQUE
Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight [JAMA] Although these trials may sometimes satisfy the standards of ethical research, the research oversight system in the United States is not sufficiently robust to ensure that this will always be the case.
	6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
A world-renowned placebo researcher asks, “Does placebo research boost pseudoscience?” [Science-Based Medicine] Professor Fabrizio Benedetti is the most famous and almost certainly also the most influential researcher investigating the physiology of placebo effects. In a recent commentary, he asks whether placebo research is fueling quackery, as quacks co-opt its results. The answer to that question is certainly yes. A better question is: How do supporters of science counter the placebo narrative promoted by quacks, in which placebos represent the “power of the mind to heal the body”?
	6.6 PUBLICATIONS
Signaling the trustworthiness of science [PNAS] A number of approaches for authors and journals would lead to more effective signals of trustworthiness at the article level. These include article badging, checklists, a more extensive withdrawal ontology, identity verification, better forward linking, and greater transparency.
	6.7 DMP, BIG DATA & APPLIS
Healthcare data hacking could lead to identity thefts [Reuters] Overall, 71% of the hacks that occurred over the 10-year study period, affecting 159 million patients, compromised sensitive demographic or financial information that could be used in identity theft and financial fraud, the researchers concluded.